Pharmacogenomics, a portmanteau of pharmacology and genomics sometimes abbreviated as PGx, is the study of how an individual’s genetic variation affects their response to medication. The aim of ...

Wasatch BioLabs (WBL), a Renew Biotechnologies subsidiary, and the largest U.S. sequencing service provider dedicated exclusively to long-read sequencing, today announced the addition of three Oxford ...

The ultimate goal of pharmacologic management of disease is to maximize the efficacy of therapeutic agents while minimizing their toxicity; the need to attain this goal is inherently more pronounced ...

Clinical trials offer a slew of benefits: optimal dosage ranges, identified potential side effects, and efficacy data. If approved by the FDA, clinicians leverage the insights from Phase III trials to ...

Pharmacogenomics has had rapid implementation over the past decade, with recent growth in application in oncology, mental health, solid organ transplantation, and more. There has been much focus on ...

A recent joint report from the Royal College of Physicians and the British Pharmacological Society has outlined guidance, barriers and opportunities around the use of pharmacogenomics – using genomics ...

Genetic polymorphisms have been described in the case of several CYP isoenzymes. The best explored example of this phenomenon is the CYP2C19 polymorphism. In this table the most frequent alleles are ...

The field of pharmacogenomics integrates genomic data with pharmacology to customize drug treatments for individual patients. This presentation aims to educate clinical researchers and healthcare ...